NCT01386671 - Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

January 31, 2018

Conditions

Type 2 Diabetes

Interventions

DRUG

Metformin glycinate

Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily

DRUG

Metformin hydrochloride

12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).

Trial Locations (4)

44600

Instituto de terapéutica experimental y clínica (INTEC), Guadalajara

03800

Paracelsus S.A. de C.V., Mexico City

06600

Unidad Antidiabética Integral, Mexico City

06720

Unidad de Investigacion en Epidemiologia Clinica. UMAE Hospital de Especialidades Centro Medico Nacional Siglo XXI. Instituto Mexicano del Seguro Social, Mexico City

All Listed Sponsors

lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY